Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. View here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksValiRx Share News (VAL)

Share Price Information for ValiRx (VAL)

Share Price is delayed by 15 minutes
Get Live Data
0.165    0.00 (0.00%)
Bid:
0.16
Ask:
0.17
Spread: 0.01 (6.25%)
Market Cap: £2.18m
VAL Live PriceLast checked at - London Stock Exchange

Intraday ValiRx Share Chart

Small caps: Cineworld, Aortech, African Eagle

Mon, 24th May 2010 07:52
Cinema chain Cineworld has signed a deal with Quintain Estates for a new multi-screen cinema at Wembley City, the retail park next door to Wembley station. Cineworld has signed a 25 year lease for a new nine screen cinema which will seat 1,800 people in total and is scheduled to open in 2013. It will be located adjacent to Wembley Stadium and Wembley Arena, forming a central part of the 280,000 sq ft leisure and retail hub. Construction is expected to commence on the site in 2011.Biomaterials and medical devices group Aortech today announced a non-exclusive technology licence and material supply agreement with a multi-billion dollar NYSE listed company to use the group's proprietary biostable co-polymer Elast-Eo as an integral part of a drug delivery platform for urological catheters.African Eagle is "delighted" with results of its phase 2 column and tank leach tests at the Dutwa nickel project in Tanzania.The tests show that Dutwa ore could be processed by either heap leaching or tank leaching at normal atmospheric pressure, without recourse to the high cost and hi-tech complications of high pressure acid leach (HPAL).Green technology company Ultima Networks made a pre-tax profit of £214,000 in 2009, down from £281,000 the previous year, on revenue down to £1.87m from £1.98m. "There remain challenges ahead in the economic conditions we face which will have an impact on all divisions of the business but we are confident that the milestones reached in 2009 will allow us to grow across all areas of the group," the firm said.It's also confident it will be able to raise enough money to build the solar parks planned for southern Italy.ValiRx, the biotech firm focused on cancer diagnostics and therapeutics for personalised medicine, has added an over the counter Chlamydia self-testing kit to its range of health screening products.The company has signed an agreement to market Biovei's Chlamydia kit in the UK and Ireland under ValiRx's SELFCheck brand. The SELFCheck Chlamydia kit will provide a test result within about 10 minutes, compared to a lag of four to five days for a laboratory test. Trading systems developer Patsystems said results for the year to end of April were in line with management's expectations while the company's strong pipeline underpins its belief that 2010 will be another strong year for the group."I am pleased to report that 2010 has started as strongly as we expected with the addition of Bursa Malaysia to our client list, good progress on several other sales prospects and continued double digit growth in our existing Asian client base," said Richard Last, the company's chairman.Oil and gas firm Roxi Petroleum narrowed pre-tax losses to $33.4m against the loss of $94.5m predominantly due to lower admin costs. "These are exciting times for Roxi and its shareholders, as we remain focused on increasing shareholder value in the near term. We are looking forward to a very active and productive period ahead of us," he said.Stratex International rose after the exploration and development company announced "positive results" from detailed sampling of the company's Megenta hot spring gold discovery in Ethiopia.Shares in Max Petroleum fell back after the Kazakhstan-focused oil and gas developer said reservoirs encountered during drilling at the Borkyldakty Field were 'structurally lower than expected, at or below their respective oil-water contacts.'

Related News

TRADING UPDATES: Maintel fundraising completes; ValiRx ends deal
22 Jun 2026

TRADING UPDATES: Maintel fundraising completes; ValiRx ends deal

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Monday and not separately reported by Alliance News:

IN BRIEF: ValiRx subsidiary Cytolytix granted "core" European patent
27 May 2026

IN BRIEF: ValiRx subsidiary Cytolytix granted "core" European patent

ValiRx PLC - London-based life science company - Majority-owned subsidiary Cytolytix Ltd has its European patent "Nanoparticle for Anti-Cancer Peptide...

TRADING UPDATES: IAG launches new buyback; Forgent settles legal case
15 May 2026

TRADING UPDATES: IAG launches new buyback; Forgent settles legal case

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Friday and not separately reported by Alliance News:

ValiRx News

ValiRx Submits Application For VAL201 Cancer Study
10 Jun 2014

ValiRx Submits Application For VAL201 Cancer Study

LONDON (Alliance News) - ValiRx PLC said Tuesday that it has submitted an application to the Medicines and Healthcare Products Regulatory Agency for a...

Tuesday broker round-up UPDATE
10 Jun 2014

Tuesday broker round-up UPDATE

ASOS: Goldman Sachs reduces target price from 6250p to 5750p, while upgrading to strong buy. Avon Rubber: Investec lowers target price from 690p to 6...

ValiRx Sees Progress On Cancer Drug Development From Joint Venture
15 May 2014

ValiRx Sees Progress On Cancer Drug Development From Joint Venture

LONDON (Alliance News) - ValiRx PLC said Thursday that it had seen promising progress on the development of its cancer treatment VAL401 towards Phase ...

ValiRx Granted Patent For Cancer Screening Biomarker In Japan
1 May 2014

ValiRx Granted Patent For Cancer Screening Biomarker In Japan

LONDON (Alliance News) - ValiRx PLC said Thursday that it had been granted a patent in Japan for its cancer screening test gene biomarker NAV3. The bi...

ValirX In Joint Venture With Tangent Reprofiling For Cancer Drug Development
8 Apr 2014

ValirX In Joint Venture With Tangent Reprofiling For Cancer Drug Development

LONDON (Alliance News) - ValiRx PLC Tuesday said it has established a risk-sharing joint venture with Tangent Reprofiling Ltd which will progress Tang...

ValiRx Anti-Cancer Compound To Undergo Further Study
1 Apr 2014

ValiRx Anti-Cancer Compound To Undergo Further Study

LONDON (Alliance News) - ValiRx PLC said Tuesday that its clinical trial project team for its anti-cancer compound VAL201 has recommended a further st...

ValiRx Loss Widens As It Ups Investment In Clinical Trial Programme
19 Mar 2014

ValiRx Loss Widens As It Ups Investment In Clinical Trial Programme

LONDON (Alliance News) - Biotechnology company ValiRx PLC Wednesday posted a widened pretax loss in 2013 as revenue declined, and it upped investment ...

ValiRx Biomarket Receives European Patent Approval
20 Feb 2014

ValiRx Biomarket Receives European Patent Approval

LONDON (Alliance News) - ValiRx PLC Thursday said a cancer screening test gene biomarker called NAV3, acquired by its subsidiary in 2012, has received...